Hormone Receptor-positive Metastatic Breast Cancer

• CLINICAL_TRIALS research · 2025-08-12
  Clinical Trial Update: Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC [Phase 2]

  Phase 2 clinical trial update examining determinants of resistance to endocrine therapy and the effect of a CDK4/6 inhibitor in hormone rece…

• CLINICAL_TRIALS research · 2025-05-16
  Clinical Trial Update: Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management [Phase 4]

  This document describes a Phase 4 clinical trial evaluating the combination of abemaciclib with endocrine therapy for hormone receptor-posit…

• CLINICAL_TRIALS research · 2025-03-25
  Clinical Trial Update: Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors [Phase 1, Phase 2]

  Phase 1/2 study of Sacituzumab Govitecan in Japanese participants with advanced solid tumors is ongoing, including metastatic triple-negativ…

• CLINICAL_TRIALS trial_result · 2019-07-15
  Clinical Trial Update: A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer [Phase 3]

  Phase 3 clinical trial evaluating the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab, or both for …

• CLINICAL_TRIALS research · 2015-12-29
  Clinical Trial Update: Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

  This entry reports the completion of a Danish observational study evaluating everolimus plus exemestane in HR-positive, HER2-negative metast…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.